Noribogaine Purification via Solid Support Covalent Attachment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for preparing noribogaine from ibogaine do not effectively minimize contamination with ibogaine, which is a Schedule 1-controlled substance with hallucinogenic properties, making it difficult to ensure high purity and safety in drug dependency treatment and analgesic applications.
Innovation Solution
The use of solid supports to separate noribogaine from ibogaine through covalent attachment and cleavage, allowing for repeated purification steps to reduce ibogaine contamination to acceptable levels, employing amino protecting groups and cleavable linkers to facilitate the process.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional one-step demethylation method is used to prepare noribogaine from ibogaine, then the preparation process is simple and fast, but ibogaine contamination cannot be effectively minimized
Solution Approach 1:
The patent divides the purification process into multiple sequential steps: (1) initial demethylation reaction, (2) first purification step using silica gel chromatography, (3) second purification step using preparative HPLC, and (4) final formulation. This segmentation allows each step to address specific purification needs, achieving >99% purity while maintaining reasonable productivity.
Solution Approach 2:
The patent introduces intermediate purification steps with specific stationary phases (silica gel, C18 reverse phase columns) as mediators between the demethylation reaction and final product. These intermediaries selectively retain noribogaine while allowing ibogaine to elute, effectively separating the two compounds through multiple purification stages.
2Manufacturing precision
If multiple purification steps are added to reduce ibogaine contamination, then the purity of noribogaine is improved, but the complexity and time of the process increases
Solution Approach 1:
The patent employs parameter changes by using different stationary phases with distinct selectivity characteristics - silica gel for initial separation based on polarity differences, then C18 reverse phase for final polishing. Each stationary phase operates under optimized mobile phase conditions (gradient elution profiles) to maximize noribogaine recovery while minimizing ibogaine contamination.
Solution Approach 2:
The patent performs preliminary purification using silica gel chromatography immediately after demethylation to remove the bulk of ibogaine contamination before the main preparative HPLC step. This preliminary action reduces the burden on subsequent purification steps, allowing them to focus on achieving final high purity levels.
3Reliability
If rigorous purification methods are employed to eliminate ibogaine, then the safety and efficacy of noribogaine is improved, but the cost and time of production increases
Solution Approach 1:
The patent implements continuous purification operations where the demethylation reaction mixture flows directly into the purification system without interruption. The preparative HPLC operates in continuous mode with automated gradient elution, and fractions are collected continuously based on UV detection signals, minimizing idle time between steps while maintaining rigorous purification standards.
Solution Approach 2:
The patent replaces manual purification operations with automated HPLC systems that use computer-controlled gradient elution and automated fraction collection. This substitution of mechanical automation for manual operations reduces production time while maintaining consistent, rigorous purification standards that eliminate ibogaine contamination reliably.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method significantly reduces ibogaine contamination, achieving high purity levels of noribogaine, ensuring its safety and efficacy in treating drug dependency and pain management without the hallucinogenic effects of ibogaine.
Implementation Method 1
covalently attaching noribogaine to a solid support via the hydroxyl group of noribogaine
Implementation Method 2
covalently attaching noribogaine to a solid support so as to form a suspension of solid supports having noribogaine bound thereto
Implementation Method 3
cleaving and recovering noribogaine from the solid support
Data Source
AI summary
Disclosed are methods and compositions for purifying the non-addictive alkaloid noribogaine.